Clinical Trials on Esophageal Squamous Cell Carcinoma

Total 12976 results

BeiGene

Completed

AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

Korea, Republic of, Spain, China, Thailand, Taiwan, France
Yuhong Li

Completed

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment (Poetry-1)

Esophageal Squamous Cell Carcinoma

China
Peking University

Unknown

Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

Esophageal Squamous Cell Carcinoma

China
Mian XI

Completed

Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

Unresectable Esophageal Cancer

China
Centre Oscar Lambret
National Cancer Institute, France

Terminated

Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer. (E-DIS)

Squamous Cell Carcinoma of Esophagus

France
Daping Hospital and the Research Institute of Surgery...

Enrolling by invitation

PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer (PPIO-004-EC001)

Esophageal Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital

Unknown

A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Nanfang Hospital of Southern Medical University

Unknown

Exploration and Verification of DNA Methylolation in Early Screening of Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Merus N.V.

Recruiting

A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Non-Small Cell Lung Cancer Metastatic

United States, Spain, France, Italy, Netherlands, Belgium, Korea, Republic of, Germany, Singapore
Hebei Medical University Fourth Hospital

Not yet recruiting

Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma

Aspirin as an Adjuvant Therapy, to Observe Its Effect on the Disease Free Survival Rate of Patients With Esophageal Squamous Cell Carcinoma

China
Shandong University

Completed

Artificial Intelligence for Early Diagnosis of Esophageal Squamous Cell Carcinoma

Artificial Intelligence | Optical Enhancement Endoscopy | Magnifying Endoscopy

China
Guo Xufeng

Recruiting

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Adjuvant Therapy | Neoadjuvant Chemoimmunotherapy

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Fuzhou General Hospital

Recruiting

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Immunotherapy Esophagus Cancer

China
Fudan University

Recruiting

ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004) (HYPERION)

Esophageal Squamous Cell Carcinoma

China
Daping Hospital and the Research Institute of Surgery...

Active, not recruiting

PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy

Esophageal Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.
Fortrea

Completed

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) (ORIENT-15)

Esophageal Squamous Cell Carcinoma

France, Spain, Belgium, Australia, United States, China, Hungary
UNC Lineberger Comprehensive Cancer Center

Completed

HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi

Esophageal Squamous Cell Carcinoma

Malawi
Fudan University

Completed

Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Neoplasms

China
Sichuan Cancer Hospital and Research Institute

Unknown

Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Reconstruction

Esophageal Squamous Cell Carcinoma

China
Shanghai Chest Hospital
First Affiliated Hospital of Suzhou Medical College

Unknown

KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Yonsei University

Completed

A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

Esophageal Squamous Cell Carcinoma

Korea, Republic of
Ohio State University Comprehensive Cancer Center
National Comprehensive Cancer Network; Spectrum Pharmaceuticals, Inc

Completed

Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy

Squamous Cell Carcinoma of the Esophagus | Adenocarcinomas of the Gastroesophageal Junction | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer

United States
The First Affiliated Hospital with Nanjing Medical...
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Shanghai Chest Hospital
Chang Gung Memorial Hospital; Tianjin Medical University Cancer Institute and... and other collaborators

Unknown

Pre-Surgery If Needed for Oesophageal Cancer (preSINO)

Esophageal Cancer

China, Hong Kong, Taiwan
Cancer Institute and Hospital, Chinese Academy...

Completed

Endoscopic Screening on Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University

Unknown

ESI With EUS to Differentiate T3 and T4 ESCC (ESI)

Esophageal Cancer

China
University of Michigan Rogel Cancer Center

Terminated

Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus

Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus

United States
Sichuan Cancer Hospital and Research Institute

Recruiting

Outcomes of Smoker and Drinker With Esophageal Squamous Cell Carcinoma After Esophagectomy (OSinEC)

Outcomes of Smoker and Drinker After Esophagectomy

China
Fudan University

Active, not recruiting

Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)

Esophageal Squamous Cell Carcinoma | Esophagus Cancer | Postoperative | Chemoradiotherapy | Radiation Therapy

China
Jules Bordet Institute
Innate Pharma

Withdrawn

Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA (ARTEMIS-Eso)

Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus

Belgium
Samsung Medical Center

Unknown

Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma (XP versus XT)

First Line Chemotherapy | Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel | Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Korea, Republic of
Sun Yat-sen University
Affiliated Cancer Hospital of Shantou University Medical College

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Esophageal Cancer | Oesophageal Cancer | Squamous Cell Esophageal Carcinoma

China
Affiliated Hospital of Nantong University

Recruiting

PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC

Esophageal Squamous Cell Carcinoma

China
Chuangzhen Chen

Completed

Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer

Esophageal Neoplasms

China
Beijing Friendship Hospital

Unknown

Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols (CREAT)

Carcinoma, Squamous Cell

China
Anhui Provincial Hospital

Recruiting

Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer

Esophageal Squamous Cell Carcinoma | Chemoradiotherapy | Initial Inoperable

China
Morten Mau-Sørensen
Odense University Hospital; Aarhus University Hospital; Aalborg University Hospital

Recruiting

Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients (HERES)

Esophageal Squamous Cell Carcinoma | HER-2 Gene Amplification | HER-2 Protein Overexpression

Denmark
National Taiwan University Hospital
Merck Sharp & Dohme LLC

Recruiting

Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence

Esophageal Squamous Cell Carcinoma

Taiwan
Xiaomeng Zheng

Enrolling by invitation

A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma

Radiotherapy | Esophagus Cancer | Endoscopic Mucosal Resection

China
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

Esophageal Squamous Cell Carcinoma

China
Xijing Hospital of Digestive Diseases
Ankang Central Hospital; Xi'an International Medical Center Hospital; The First... and other collaborators

Recruiting

High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC

Esophageal Squamous Cell Carcinoma

China
Xijing Hospital of Digestive Diseases

Completed

The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy

Esophageal Squamous Cell Carcinoma

China
Fifth Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC

Esophageal Squamous Cell Carcinoma | Benign Lymph Node Neoplasm | Malignant Lymph Node Neoplasm
Fudan University
RenJi Hospital; Shanghai Chest Hospital; Shanghai General Hospital, Shanghai... and other collaborators

Unknown

Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy (Nimotuzumab)

Esophageal Squamous Cell Carcinoma

China
Shandong Luye Pharmaceutical Co., Ltd.

Unknown

A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma

Esophageal Carcinoma

China
Changhai Hospital
Shanghai Municipal Science and Technology Commission

Completed

Esophageal cAncer Screening Trial (EAST)

Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma

United States

Clinical Trials on Esophageal Squamous Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations